![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-7-2023-80553.pdf
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-gets-usfda-nod-for-generic-drug-with-180-day-exclusivity/articleshow/98934035.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.globenewswire.com/news-release/2022/09/15/2516825/0/en/EPI-Health-a-Novan-Company-and-MC2-Therapeutics-Present-WYNZORA-calcipotriene-and-betamethasone-dipropionate-Cream-0-005-0-064-Subgroup-Data-Analysis-at-Skin-of-Color-Update-2022-C.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-6-2022-1657105109.pdf
https://health.economictimes.indiatimes.com/news/pharma/glenmark-receives-anda-approval-for-topical-treatment-of-plaque-psoriasis-in-adults/91434978
https://finance.yahoo.com/news/epi-health-mc2-therapeutics-announce-130000824.html
https://leo-pharma.com/media-center/news/leo-pharma-announces-us-fda-approval-for-enstilar-foam
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212367
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213269
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-enstilar-207589-calcipotriene-and-betamethasone-dipropionate-topical-foam00050064-1597494793.pdf
https://www.b3cnewswire.com/202007222098/mc2-therapeutics-announces-u-s-food-and-drug-administration-approval-of-wynzora-cream-calcipotriene-and-betamethasone-dipropionate-w-w-0-005-0-064-for-adults-with-plaque-psoriasis.html
https://www.biospectrumasia.com/news/39/16250/lipidor-cadila-to-conduct-ph-iii-study-of-anti-psoriasis-candidate.html
https://www.businesswire.com/news/home/20200612005254/en/LEO-Pharma-Presents-Results-Study-Twice-Weekly-Enstilar%C2%AE
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210765
https://www.businesswire.com/news/home/20190924005192/en/Bicycle-Therapeutics-Present-Updated-Data-Phase-IIIa/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.businesswire.com/news/home/20190731005636/en/LEO-Pharma-Announces-U.S.-Food-Drug-Administration/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J
https://www.biospectrumasia.com/news/33/13521/fda-approves-soriluxr-for-adolescent-plaque-psoriasis.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-28-2018-1519803579.pdf
http://www.drugstorenews.com/article/fda-approves-lupins-generic-dovonex-scalp-solution
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207163
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-15-2017-1489584258.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-22-2017-1487758756.pdf
http://www.pharmatimes.com/news/smc_green_light_for_leos_enstilar_1132237
http://www.prnewswire.com/news-releases/leo-pharma-receives-scientific-approval-of-enstilar-for-the-treatment-of-psoriasis-in-eu-572901011.html
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/205772Orig1s000ltr.pdf
http://www.fiercepharmamanufacturing.com/story/attix-pharmaceuticals-recalls-hundreds-apis-us/2015-04-30